1. PACKAGE INSERT

SPECTRACEF® TABLETS

(cefditoren pivoxil)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF and other antibacterial drugs, SPECTRACEF should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.

OT00617C

300780-0C-001

DESCRIPTION

SPECTRACEF tablets contain cefditoren pivoxil, a semi-synthetic cephalosporin antibiotic for oral administration. It is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active cefditoren.

Chemically, cefditoren pivoxil is \((-\)-(6R,7R)-2,2-dimethylpropionyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy-iminoacetamido]-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. The empirical formula is C\(_{25}\)H\(_{28}\)N\(_6\)O\(_7\)S\(_3\) and the molecular weight is 620.73. The structural formula of cefditoren pivoxil is shown below:

![Structural formula of cefditoren pivoxil](image)

The amorphous form of cefditoren pivoxil developed for clinical use is a light yellow powder. It is freely soluble in dilute hydrochloric acid and soluble at levels equal to 6.06 mg/mL in ethanol and <0.1 mg/mL in water.
SPECTRACEF® (cefditoren pivoxil) tablets contain 200 mg of cefditoren as cefditoren pivoxil and the following inactive ingredients: croscarmellose sodium, D-mannitol, hydroxypropyl cellulose, hypromellose, magnesium stearate, sodium caseinate (a milk protein), and sodium tripolyphosphate. The tablet coating contains carnauba wax, hypromellose, polyethylene glycol, and titanium dioxide. Tablets are printed with ink containing D&C Red No. 27, FD&C Blue No. 1, propylene glycol, and shellac.

**CLINICAL PHARMACOLOGY**

**Pharmacokinetics**

**Absorption**

*Oral Bioavailability*

Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases. Maximal plasma concentrations ($C_{\text{max}}$) of cefditoren under fasting conditions average 1.8 ± 0.6 µg/mL following a single 200 mg dose and occur 1.5 to 3 hours following dosing. Less than dose-proportional increases in $C_{\text{max}}$ and area under the concentration-time curve (AUC) were observed at doses of 400 mg and above. Cefditoren does not accumulate in plasma following twice daily administration to subjects with normal renal function. Under fasting conditions, the estimated absolute bioavailability of cefditoren pivoxil is approximately 14%. The absolute bioavailability of cefditoren pivoxil administered with a low fat meal (693 cal, 14 g fat, 122 g carb, 23 g protein) is 16.1 ± 3.0%.

*Food Effect*

Administration of cefditoren pivoxil following a high fat meal (858 cal, 64 g fat, 43 g carb, 31 g protein) resulted in a 70% increase in mean AUC and a 50% increase in mean $C_{\text{max}}$ compared to administration of cefditoren pivoxil in the fasted state. After a high fat meal, the $C_{\text{max}}$ averaged 3.1 ± 1.0 µg/mL following a single 200 mg dose of cefditoren pivoxil and 4.4 ± 0.9 µg/mL following a 400 mg dose. Cefditoren AUC and $C_{\text{max}}$ values from studies conducted with a moderate fat meal (648 cal, 27 g fat, 73 g carb, 29 g protein) are similar to those obtained following a high fat meal.

**Distribution**

The mean volume of distribution at steady state ($V_{\text{ss}}$) of cefditoren is 9.3 ± 1.6 L. Binding of cefditoren to plasma proteins averages 88% from *in vitro* determinations, and is concentration-independent at cefditoren concentrations ranging from 0.05 to 10 µg/mL. Cefditoren is primarily bound to human serum albumin and its binding is decreased when serum albumin concentrations are reduced. Binding to α-1-acid glycoprotein ranges from 3.3 to 8.1%. Penetration into red blood cells is negligible.


Skin blister fluid

Maximal concentrations of cefditoren in suction-induced blister fluid were observed 4 to 6 hours following administration of a 400 mg dose of cefditoren pivoxil with a mean of 1.1 ± 0.42 µg/mL. Mean blister fluid AUC values were 56 ± 15% of corresponding plasma concentrations.

Tonsil tissue

In fasted patients undergoing elective tonsillectomy, the mean concentration of cefditoren in tonsil tissue 2 to 4 hours following administration of a 200 mg dose of cefditoren pivoxil was 0.18 ± 0.07 µg/g. Mean tonsil tissue concentrations of cefditoren were 12 ± 3% of the corresponding serum concentrations.

Cerebrospinal Fluid (CSF)

Data on the penetration of cefditoren into human cerebrospinal fluid are not available.

Metabolism and Excretion

Cefditoren is eliminated from the plasma, with a mean terminal elimination half-life (t½) of 1.6 ± 0.4 hours in young healthy adults. Cefditoren is not appreciably metabolized. After absorption, cefditoren is mainly eliminated by excretion into the urine, with a renal clearance of approximately 4-5 L/h. Studies with the renal tubular transport blocking agent probenecid indicate that tubular secretion, along with glomerular filtration is involved in the renal elimination of cefditoren. Cefditoren renal clearance is reduced in patients with renal insufficiency. (See Special Populations, Renal Insufficiency and Hemodialysis.)

Hydrolysis of cefditoren pivoxil to its active component, cefditoren, results in the formation of pivalate. Following multiple doses of cefditoren pivoxil, greater than 70% of the pivalate is absorbed. Pivalate is mainly eliminated (>99%) through renal excretion, nearly exclusively as pivaloylcarnitine. Following a 200 mg BID regimen for 10 days, the mean decrease in plasma concentrations of total carnitine was 18.1 ± 7.2 nmole/mL, representing a 39% decrease in plasma carnitine concentrations. Following a 400 mg BID regimen for 14 days, the mean decrease in plasma concentrations of carnitine was 33.3 ± 9.7 nmole/mL, representing a 63% decrease in plasma carnitine concentrations. Plasma concentrations of carnitine returned to the normal control range within 7 to 10 days after discontinuation of cefditoren pivoxil. (See PRECAUTIONS, General and CONTRAINDICATIONS.)

Special Populations

Geriatric

The effect of age on the pharmacokinetics of cefditoren was evaluated in 48 male and female subjects aged 25 to 75 years given 400 mg cefditoren pivoxil BID for 7 days. Physiological
changes related to increasing age increased the extent of ceftitoren exposure in plasma, as evidenced by a 26% higher $C_{\text{max}}$ and a 33% higher AUC for subjects aged $\geq 65$ years compared with younger subjects. The rate of elimination of ceftitoren from plasma was lower in subjects aged $\geq 65$ years, with $t_{1/2}$ values 16-26% longer than for younger subjects. Renal clearance of ceftitoren in subjects aged $\geq 65$ years was 20-24% lower than in younger subjects. These changes could be attributed to age-related changes in creatinine clearance. No dose adjustments are necessary for elderly patients with normal (for their age) renal function.

**Gender**

The effect of gender on the pharmacokinetics of ceftitoren was evaluated in 24 male and 24 female subjects given 400 mg ceftitoren pivoxil BID for 7 days. The extent of exposure in plasma was greater in females than in males, as evidenced by a 14% higher $C_{\text{max}}$ and a 16% higher AUC for females compared to males. Renal clearance of ceftitoren in females was 13% lower than in males. These differences could be attributed to gender-related differences in lean body mass. No dose adjustments are necessary for gender.

**Renal Insufficiency**

Ceftitoren pharmacokinetics were investigated in 24 adult subjects with varying degrees of renal function following administration of ceftitoren pivoxil 400 mg BID for 7 days. Decreased creatinine clearance ($CL_{\text{cr}}$) was associated with an increase in the fraction of unbound ceftitoren in plasma and a decrease in the ceftitoren elimination rate, resulting in greater systemic exposure in subjects with renal impairment. The unbound $C_{\text{max}}$ and AUC were similar in subjects with mild renal impairment ($CL_{\text{cr}}$: 50-80 mL/min/1.73 m$^2$) compared to subjects with normal renal function ($CL_{\text{cr}}$: $>80$ mL/min/1.73 m$^2$). Moderate ($CL_{\text{cr}}$: 30-49 mL/min/1.73 m$^2$) or severe ($CL_{\text{cr}}$: $<30$ mL/min/1.73 m$^2$) renal impairment increased the extent of exposure in plasma, as evidenced by mean unbound $C_{\text{max}}$ values 90% and 114% higher and AUC values 232% and 324% higher than that for subjects with normal renal function. The rate of elimination from plasma was lower in subjects with moderate or severe renal impairment, with respective mean $t_{1/2}$ values of 2.7 and 4.7 hours. No dose adjustment is necessary for patients with mild renal impairment ($CL_{\text{cr}}$: 50-80 mL/min/1.73 m$^2$). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment ($CL_{\text{cr}}$: 30-49 mL/min/1.73 m$^2$) and 200 mg QD be administered to patients with severe renal impairment ($CL_{\text{cr}}$: $<30$ mL/min/1.73 m$^2$). (See **DOSAGE AND ADMINISTRATION**.)

**Hemodialysis**

Ceftitoren pharmacokinetics investigated in six adult subjects with end-stage renal disease (ESRD) undergoing hemodialysis given a single 400 mg dose of ceftitoren pivoxil were highly variable. The mean $t_{1/2}$ was 4.7 hours and ranged from 1.5 to 15 hours. Hemodialysis (4 hours duration) removed approximately 30% of ceftitoren from systemic circulation but did not change the apparent terminal elimination half-life. The appropriate dose for ESRD patients has not been determined. (See **DOSAGE AND ADMINISTRATION**.)
**Hepatic Disease**

Cefditoren pharmacokinetics were evaluated in six adult subjects with mild hepatic impairment (Child-Pugh Class A) and six with moderate hepatic impairment (Child-Pugh Class B). Following administration of cefditoren pivoxil 400 mg BID for 7 days in these subjects, mean C_{max} and AUC values were slightly (<15%) greater than those observed in normal subjects. No dose adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). The pharmacokinetics of cefditoren in subjects with severe hepatic impairment (Child-Pugh Class C) have not been studied.

**Microbiology**

Cefditoren is a cephalosporin with antibacterial activity against gram-positive and gram-negative pathogens. The bactericidal activity of cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefditoren is stable in the presence of a variety of β-lactamases, including penicillinas and some cephalosporinases.

Cefditoren has been shown to be active against most strains of the following bacteria, both in vitro and in clinical infections, as described in the INDICATIONS AND USAGE section.

**Aerobic Gram-Positive Microorganisms**

*Staphylococcus aureus* (methicillin-susceptible strains, including β-lactamase-producing strains)

Note: Cefditoren is inactive against methicillin-resistant *Staphylococcus aureus*

*Streptococcus pneumoniae* (penicillin-susceptible strains only)

*Streptococcus pyogenes*

**Aerobic Gram-Negative Microorganisms**

*Haemophilus influenzae* (including β-lactamase-producing strains)

*Haemophilus parainfluenzae* (including β-lactamase-producing strains)

*Moraxella catarrhalis* (including β-lactamase-producing strains)

The following in vitro data are available, but their clinical significance is unknown. Cefditoren exhibits in vitro minimum inhibitory concentrations (MICs) of ≤0.125 µg/mL against most (≥90%) strains of the following bacteria; however, the safety and effectiveness of cefditoren in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.

**Aerobic Gram-Positive Microorganisms**

*Streptococcus agalactiae*

*Streptococcus* Groups C and G

*Streptococcus*, viridans group (penicillin-susceptible and -intermediate strains)
Susceptibility Tests

Dilution Techniques

Quantitative methods that are used to determine MICs provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on dilution methods\(^1\) (broth) or equivalent with standardized inoculum concentrations and standardized concentrations of cefditoren powder. The MIC values obtained should be interpreted according to the following criteria:

For testing *Haemophilus* spp.\(^a\) and *Streptococcus* spp. including *S. pneumoniae*\(^b\):

<table>
<thead>
<tr>
<th>Clinical Isolates</th>
<th>MIC (µg/mL)</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>S. pneumoniae</em></td>
<td>≤ 0.125</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td></td>
<td>0.250</td>
<td>Intermediate (I)</td>
</tr>
<tr>
<td></td>
<td>≥0.50</td>
<td>Resistant (R)</td>
</tr>
<tr>
<td><em>Haemophilus</em> spp.</td>
<td>≤ 0.125</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td></td>
<td>0.250</td>
<td>Intermediate (I)</td>
</tr>
<tr>
<td></td>
<td>≥0.50</td>
<td>Resistant (R)</td>
</tr>
<tr>
<td><em>S. pyogenes</em></td>
<td>≤ 0.125</td>
<td>Susceptible (S)</td>
</tr>
</tbody>
</table>

\(^a\)This interpretive standard is applicable only to broth microdilution susceptibility tests with *Haemophilus* spp. using *Haemophilus* Test Medium (HTM).\(^1\)

\(^b\)These interpretive standards are applicable only to broth microdilution susceptibility tests with *Streptococcus* spp. using cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood.\(^1\)

Susceptibility test criteria cannot be established for *S. aureus*.

A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of “Intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small, uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable and that other therapy should be selected.

Standardized susceptibility test procedures require the use of laboratory control bacterial strains to control the technical aspects of the laboratory procedures. Standard cefditoren powder should provide the following MICs with these quality control strains:
<table>
<thead>
<tr>
<th>Microorganisms</th>
<th>MIC Ranges (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Streptococcus pneumoniae</em>&lt;sup&gt;a&lt;/sup&gt; ATCC 49619</td>
<td>0.016-0.12</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em>&lt;sup&gt;b&lt;/sup&gt; ATCC 49766</td>
<td>0.004-0.016</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em>&lt;sup&gt;b&lt;/sup&gt; ATCC 49247</td>
<td>0.06-0.25</td>
</tr>
</tbody>
</table>

<sup>a</sup>This quality control range is applicable to only *S. pneumoniae* ATCC 49619 tested by a microdilution procedure using cation-adjusted Mueller-Hinton broth with 2-5% lysed horse blood.<sup>1</sup>

<sup>b</sup>This quality control range is applicable to only *H. influenzae* ATCC 49247 and ATCC 49766 tested by a microdilution procedure using HTM.<sup>1</sup>

**INDICATIONS AND USAGE**

SPECTRA<sup>CE</sup> (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below.

**Acute Bacterial Exacerbation of Chronic Bronchitis** caused by *Haemophilus influenzae* (including β-lactamase-producing strains), *Haemophilus parainfluenzae* (including β-lactamase-producing strains), *Streptococcus pneumoniae* (penicillin-susceptible strains only), or *Moraxella catarrhalis* (including β-lactamase-producing strains).

**Community-Acquired Pneumonia** caused by *Haemophilus influenzae* (including β-lactamase-producing strains), *Haemophilus parainfluenzae* (including β-lactamase-producing strains), *Streptococcus pneumoniae* (penicillin-susceptible strains only), or *Moraxella catarrhalis* (including β-lactamase-producing strains).

**Pharyngitis/Tonsillitis** caused by *Streptococcus pyogenes*. NOTE: SPECTRACEF is effective in the eradication of *Streptococcus pyogenes* from the oropharynx. SPECTRACEF has not been studied for the prevention of rheumatic fever following *Streptococcus pyogenes* pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.

**Uncomplicated Skin and Skin-Structure Infections** caused by *Staphylococcus aureus* (including β-lactamase-producing strains) or *Streptococcus pyogenes*.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF and other antibacterial drugs, SPECTRACEF should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
CONTRAINDICATIONS

SPECTRACEF is contraindicated in patients with known allergy to the cephalosporin class of antibiotics or any of its components.

SPECTRACEF is contraindicated in patients with carnitine deficiency or inborn errors of metabolism that may result in clinically significant carnitine deficiency, because use of SPECTRACEF causes renal excretion of carnitine. (See PRECAUTIONS, General.)

SPECTRACEF® tablets contain sodium caseinate, a milk protein. Patients with milk protein hypersensitivity (not lactose intolerance) should not be administered SPECTRACEF.

WARNINGS

BEFORE THERAPY WITH SPECTRACEF (CEFDITOREN PIVOXIL) IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFDITOREN PIVOXIL, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFDITOREN PIVOXIL IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-HYPERSENSITIVITY AMONG β-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFDITOREN PIVOXIL OCCURS, THE DRUG SHOULD BE DISCONTINUED. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including cefditoren pivoxil, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile (C. difficile) is a primary cause of antibiotic-associated colitis.

After the diagnosis of pseudomembranous colitis has been established, appropriate therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against C. difficile colitis.
PRECAUTIONS

General

Prescribing SPECTRACEF® in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

SPECTRACEF is not recommended when prolonged antibiotic treatment is necessary, since other pivalate-containing compounds have caused clinical manifestations of carnitine deficiency when used over a period of months. No clinical effects of carnitine decrease have been associated with short-term treatment. The effects on carnitine concentrations of repeat short-term courses of SPECTRACEF are not known.

In community-acquired pneumonia patients (N=192, mean age 50.3 ± 17.2 years) given a 200 mg BID regimen for 14 days, the mean decrease in serum concentrations of total carnitine while on therapy was 13.8 ± 10.8 nmole/mL, representing a 30% decrease in serum carnitine concentrations. In community-acquired pneumonia patients (N=192, mean age 51.3 ± 17.8 years) given a 400 mg BID regimen for 14 days, the mean decrease in serum concentrations of total carnitine while on therapy was 21.5 ± 13.1 nmole/mL, representing a 46% decrease in serum carnitine concentrations. Plasma concentrations of carnitine returned to the normal control range within 7 days after discontinuation of cefditoren pivoxil. Comparable decreases in carnitine were observed in healthy volunteers (mean age 33.6 ± 7.4 years) following a 200 mg or 400 mg BID regimen. (See CLINICAL PHARMACOLOGY.) Community-acquired pneumonia clinical trials demonstrated no adverse events attributable to decreases in serum carnitine concentrations.

However, some sub-populations (e.g., patients with renal impairment, patients with decreased muscle mass) may be at increased risk for reductions in serum carnitine concentrations during cefditoren pivoxil therapy. Furthermore, the appropriate dose in patients with end-stage renal disease has not been determined. (See DOSAGE AND ADMINISTRATION, Patients with Renal Insufficiency).

As with other antibiotics, prolonged treatment may result in the possible emergence and overgrowth of resistant organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate alternative therapy should be administered.

Cephalosporins may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. In clinical trials, there was no difference between cefditoren and comparator cephalosporins in the incidence of increased prothrombin time.
Information for Patients

Patients should be counseled that antibacterial drugs including SPECTRACEF should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When SPECTRACEF is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by SPECTRACEF or other antibacterial drugs in the future.

SPECTRACEF® (cefditoren pivoxil) should be taken with meals to enhance absorption.

SPECTRACEF may be taken concomitantly with oral contraceptives.

It is not recommended that SPECTRACEF be taken concomitantly with antacids or other drugs taken to reduce stomach acids. (See PRECAUTIONS, Drug Interactions.)

SPECTRACEF tablets contain sodium caseinate, a milk protein. Patients with milk protein hypersensitivity (not lactose intolerance) should not be administered SPECTRACEF.

Drug Interactions

Oral Contraceptives

Multiple doses of ceftdinor pivoxil had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.

Antacids

Co-administration of a single dose of an antacid which contained both magnesium (800 mg) and aluminum (900 mg) hydroxides reduced the oral absorption of a single 400 mg dose of ceftdinor pivoxil administered following a meal, as evidenced by a 14% decrease in mean C max and an 11% decrease in mean AUC. Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.

H2-Receptor Antagonists

Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of ceftdinor pivoxil administered following a meal, as evidenced by a 27% decrease in mean C max and a 22% decrease in mean AUC. Although the clinical significance is not known, it is not recommended that ceftdinor pivoxil be taken concomitantly with H2 receptor antagonists.
Probenecid

As with other β-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean $C_{\text{max}}$, a 122% increase in mean AUC, and a 53% increase in $t_1/2$.

Drug/Laboratory Test Interactions

Cephalosporins are known to occasionally induce a positive direct Coombs’ test. A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict’s or Fehling’s solution or with CLINITEK® tablets), but not with enzyme-based tests for glycosuria (e.g., CLINISTIX®, TES-TAPE®). As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood/plasma glucose levels in patients receiving cefditoren pivoxil.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal carcinogenicity studies have been conducted with cefditoren pivoxil. Cefditoren pivoxil was not mutagenic in the Ames bacterial reverse mutation assay, or in the mouse lymphoma mutation assay at the hypoxanthine-guanine phosphoribosyltransferase locus. In Chinese hamster lung cells, chromosomal aberrations were produced by cefditoren pivoxil, but not by cefditoren. Subsequent studies showed that the chromosome aberrations were due to the release of formaldehyde from the pivoxil ester moiety in the \textit{in vitro} assay system. Neither cefditoren nor cefditoren pivoxil produced chromosomal aberrations when tested in an \textit{in vitro} human peripheral blood lymphocyte assay, or in the \textit{in vivo} mouse micronucleus assay. Cefditoren pivoxil did not induce unscheduled DNA syntheses when tested.

In rats, fertility and reproduction were not affected by cefditoren pivoxil at oral doses up to 1000 mg/kg/day, approximately 24 times a human dose of 200 mg BID based on mg/m$^2$/day.

Pregnancy-Teratogenic Effects

Pregnancy Category B

Cefditoren pivoxil was not teratogenic up to the highest doses tested in rats and rabbits. In rats, this dose was 1000 mg/kg/day, which is approximately 24 times a human dose of 200 mg BID based on mg/m$^2$/day. In rabbits, the highest dose tested was 90 mg/kg/day, which is approximately four times a human dose of 200 mg BID based on mg/m$^2$/day. This dose produced severe maternal toxicity and resulted in fetal toxicity and abortions.

In a postnatal development study in rats, cefditoren pivoxil produced no adverse effects on postnatal survival, physical and behavioral development, learning abilities, and reproductive capability at sexual maturity when tested at doses of up to 750 mg/kg/day, the highest dose tested. This is approximately 18 times a human dose of 200 mg BID based on mg/m$^2$/day.
There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Labor and Delivery**

Cefditoren pivoxil has not been studied for use during labor and delivery.

**Nursing Mothers**

Cefditoren was detected in the breast milk of lactating rats. Because many drugs are excreted in human breast milk, caution should be exercised when cefditoren pivoxil is administered to nursing women.

**Pediatric Use**

Use of cefditoren pivoxil is not recommended for pediatric patients less than 12 years of age. The safety and efficacy of cefditoren pivoxil tablets in this population, including any effects of altered carnitine concentration, have not been established. (See **PRECAUTIONS, General**.)

**Geriatric Use**

Of the 2675 patients in clinical studies who received cefditoren pivoxil 200 mg BID, 308 (12%) were >65 years of age. Of the 2159 patients in clinical studies who received cefditoren pivoxil 400 mg BID, 307 (14%) were >65 years of age. No clinically significant differences in effectiveness or safety were observed between older and younger patients. No dose adjustments are necessary in geriatric patients with normal (for their age) renal function. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See **DOSAGE AND ADMINISTRATION**.)

**ADVERSE EVENTS**

**Clinical Trials – SPECTRACEF® (cefditoren pivoxil) Tablets (Adults and Adolescent Patients ≥12 Years of Age)**

In clinical trials, 4834 adult and adolescent patients have been treated with the recommended doses of cefditoren pivoxil tablets (200 mg or 400 mg BID). Most adverse events were mild and self-limiting. No deaths or permanent disabilities have been attributed to cefditoren.

The following adverse events were thought by the investigators to be possibly, probably, or definitely related to cefditoren tablets in multiple-dose clinical trials:

<table>
<thead>
<tr>
<th>Treatment-Related Adverse Events in Trials in Adults and Adolescent Patients ≥ 12 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPECTRACEF</td>
</tr>
</tbody>
</table>

C:\Documents and Settings\davic\My Documents\SPECTRACEFlabel.doc 001  Page 12 of 16  12/20/05
<table>
<thead>
<tr>
<th>Incidence</th>
<th>Diarrhea</th>
<th>Nausea</th>
<th>Headache</th>
<th>Abdominal Pain</th>
<th>Vaginal Moniliasis</th>
<th>Dyspepsia</th>
<th>Vomiting</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=2675</td>
<td>11%</td>
<td>4%</td>
<td>3%</td>
<td>2%</td>
<td>3%</td>
<td>1%</td>
<td>1%</td>
</tr>
<tr>
<td>N=2159</td>
<td>15%</td>
<td>6%</td>
<td>2%</td>
<td>2%</td>
<td>6%</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>N=2648</td>
<td>8%</td>
<td>5%</td>
<td>2%</td>
<td>1%</td>
<td>6%</td>
<td>2%</td>
<td>2%</td>
</tr>
</tbody>
</table>

Includes amoxicillin/clavulanate, cefadroxil monohydrate, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and penicillin

1428 females
1135 females
1461 females

The overall incidence of adverse events, and in particular diarrhea, increased with the higher recommended dose of SPECTRACEF.

Treatment related adverse events experienced by <1% but >0.1% of patients who received 200 mg or 400 mg BID of cefditoren pivoxil were abnormal dreams, allergic reaction, anorexia, asthenia, asthma, coagulation time increased, constipation, dizziness, dry mouth, eructation, face edema, fever, flatulence, fungal infection, gastrointestinal disorder, hyperglycemia, increased appetite, insomnia, leukopenia, leukorrhea, liver function test abnormal, myalgia, nervousness, oral moniliasis, pain, peripheral edema, pharyngitis, pseudomembranous colitis, pruritus, rash, rhinitis, sinusitis, somnolence, stomatitis, sweating, taste perversion, thirst, thrombocytopenia, urticaria, and vaginitis.

Pseudomembranous colitis symptoms may begin during or after antibiotic treatment. (See WARNINGS.)

Sixty-one of 2675 (2%) patients who received 200 mg BID and 69 of 2159 (3%) patients who received 400 mg BID of cefditoren pivoxil discontinued medication due to adverse events thought by the investigators to be possibly, probably, or definitely associated with cefditoren therapy. The discontinuations were primarily for gastrointestinal disturbances, usually diarrhea or nausea. Diarrhea was the reason for discontinuation in 19 of 2675 (0.7%) patients who received 200 mg BID and in 31 of 2159 (1.4%) patients who received 400 mg BID of cefditoren pivoxil.

Changes in laboratory parameters of possible clinical significance, without regard to drug relationship and which occurred in ≥1% of patients who received cefditoren pivoxil 200 mg or 400 mg BID, were hematuria (3.0% and 3.1%), increased urine white blood cells (2.3% and 2.3%), decreased hematocrit (2.1% and 2.2%), and increased glucose (1.8% and 1.1%). Those events which occurred in <1% but >0.1% of patients included the following: increased/decreased white blood cells, increased eosinophils, decreased neutrophils, increased lymphocytes, increased platelet count, decreased hemoglobin, decreased sodium, increased potassium, decreased chloride, decreased inorganic phosphorus, decreased calcium, increased SGPT/ALT, increased SGOT/AST, increased cholesterol, decreased albumin,
proteinuria, and increased BUN. It is not known if these abnormalities were caused by the drug or the underlying condition being treated.

**Cephalosporin Class Adverse Reactions**

In addition to the adverse reactions listed above which have been observed in patients treated with cefditoren pivoxil, the following adverse reactions and altered laboratory test results have been reported for cephalosporin class antibiotics:

**Adverse Reactions:** Allergic reactions, anaphylaxis, drug fever, Stevens-Johnson syndrome, serum sickness-like reaction, erythema multiforme, toxic epidermal necrolysis, colitis, renal dysfunction, toxic nephropathy, reversible hyperactivity, hypertonia, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, and superinfection.

**Altered Laboratory Tests:** Prolonged prothrombin time, positive direct Coombs’ test, false-positive test for urinary glucose, elevated alkaline phosphatase, elevated bilirubin, elevated LDH, increased creatinine, pancytopenia, neutropenia, and agranulocytosis.

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. (See **DOSAGE AND ADMINISTRATION**.) If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.

**Postmarketing Experience**

The following adverse experiences, regardless of their relationship to cefditoren pivoxil, have been reported during extensive postmarketing experience, beginning with approval in Japan in 1994: pneumonia interstitial, eosinophilic pneumonia acute, acute renal failure, arthralgia, thrombocytopenia, erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis.

**OVERDOSAGE**

Information on cefditoren pivoxil overdosage in humans is not available. However, with other β-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis may aid in the removal of cefditoren from the body, particularly if renal function is compromised (30% reduction of plasma concentrations following 4 hours of hemodialysis). Treat overdosage symptomatically and institute supportive measures as required.

In acute animal toxicity studies, cefditoren pivoxil when tested at the limit oral doses of 5100 mg/kg in rats and up to 2000 mg/kg in dogs did not exhibit any health effects of concern.
Certain effects, such as diarrhea and soft stool lasting for a few days were observed in some animals as expected with most oral antibiotics due to inhibition of intestinal microflora.

**DOSAGE AND ADMINISTRATION**

(See **INDICATIONS AND USAGE** for Indicated Pathogens.)

| Table: SPECTRACEF® (cefditoren pivoxil) Dosage and Administration*  
| Adults and Adolescents (≥12 Years) |
|:---:|:---:|:---:|
| Type of Infection | Dosage | Duration (days) |
| Community-Acquired Pneumonia | 400 mg BID | 14 |
| Acute Bacterial Exacerbation of Chronic Bronchitis | 400 mg BID | |
| Pharyngitis/Tonsillitis | 200 mg BID | 10 |
| Uncomplicated Skin and Skin Structure Infections | 200 mg BID | |

*Should be taken with meals

**Patients with Renal Insufficiency**

No dose adjustment is necessary for patients with mild renal impairment (CL\text{cr}: 50-80 mL/min/1.73 m²). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (CL\text{cr}: 30-49 mL/min/1.73 m²) and 200 mg QD be administered to patients with severe renal impairment (CL\text{cr}: <30 mL/min/1.73 m²). The appropriate dose in patients with end-stage renal disease has not been determined.

**Patients with Hepatic Disease**

No dose adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). The pharmacokinetics of cefditoren have not been studied in patients with severe hepatic impairment (Child-Pugh Class C).

**HOW SUPPLIED**

SPECTRACEF® (cefditoren pivoxil) tablets containing cefditoren pivoxil equivalent to 200 mg of cefditoren are available as white, elliptical, film-coated tablets imprinted with Purdue 200 mg in blue. These tablets are available in a multi-dose tamper-evident container as follows:

**NDC 67781-181-60** Bottles of 60

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature.] Protect from light and moisture.

Dispense in a tight, light-resistant container.
Healthcare professionals can telephone Purdue’s Medical Services Department (1-888-726-7535) for information on this product.

REFERENCES


Rx Only

©2003, 2005, Purdue Pharmaceutical Products L.P.

Manufactured by:
PPL International, Inc.
Carolina, Puerto Rico 00985

Distributed by:
Purdue Pharmaceutical Products L.P.
Stamford, CT 06901-3431

U.S. Patent Nos. 4,839,350; 4,918,068; and 5,958,915

January 18, 2005

OT00617C
300780-0C-001